Enhancing HepG2 cell apoptosis with a combined nanoparticle delivery of miR-128-3p agomir and Oroxin B: A novel drug delivery approach based on PI3K-AKT and VEGF pathway crosstalk

Abstract

Hepatocellular carcinoma (HCC) shows the highest morbidity among liver cancers which is characterized by genetic mutations in hepatocytes, leading to uncontrolled cell growth and proliferation. Current treatment include surgery, chemotherapy and immunotherapy; however, chemotherapeutics, which focus on single-targeted drug therapy, are still associated with certain limitations and may affect the treatment outcomes. Natural products also show the anticancer effect of HCC and hypotoxicity, but overall low activity of natural products limits their further application. miRNAs can modulate post-transcriptional functions of target genes. An increasing body of evidence has demonstrated that miRNAs are the key regulators in HCC by targeting different molecules in different signaling pathways. However, miRNAs are fragile and liable to catabolism by RNases in serum and other body fluids, and small molecules separated from natural products may have limited bio-availability. A chitosan based, targeted, sustained-release nanoparticle delivery miR-128-3p agomir (NA-miR-128-3p) was developed in this work. This nanoparticle was prepared by pentasodium tripolyphosphate (TPP), chitosan hydrochloride and miR-128-3p agomir with target aptamer which was loaded into the chitosan nanoparticle by self-assembly. It can intervene in HCC progress by affecting AKT1 expression. Based on this, a novel, efficient, long-acting, multi-mechanism and low-dosage combination drug delivery strategy was proposed in this work and showed a prominent anti-tumor effect. NA-miR-128-3p combined with natural product Oroxin B significantly affected HCC progression by the interference with VEGF and PI3K-AKT pathways, better than using NA-miR-128-3p and Oroxin B alone. Taken together, this nanoparticle and combinative administration compensate for the shortcomings of the fragile RNA drugs and the low activity of natural products, with high prospects in HCC treatment.

Keywords

NA-miR-128-3p / Nucleic acid drug / Hepatocellular carcinoma / Oroxin B / Combinative administration

Conflicts of interest

The authors report no conflicts of interest.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant 82373828), and the National Key Technologies R&D Program of China (2023YFD1400902).

References

[1] Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, et al. Management of hepatocellular carcinoma: a review. JAMA Surg 2023; 1(4):410-20 158.

[2] Polyzos SA, Chrysavgis L, Vachliotis ID, Chartampilas E, Cholongitas E. Nonalcoholic fatty liver disease and hepatocellular carcinoma:insights in epidemiology, pathogenesis, imaging, prevention and therapy. Semin Cancer Biol 2023; 93:20-35.

[3] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol 2023; 20(12):864-84.

[4] Ochoa MC, Sanchez-Gregorio S, de Andrea CE, Garasa S, Alvarez M, Olivera I, et al. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma. Cell Rep Med 2023; 18(4):101009 4.

[5] Yu SJ. Immunotherapy for hepatocellular carcinoma: recent advances and future targets. Pharmacol Ther 2023; 244:108387.

[6] Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics 2023; 15(7):1796.

[7] Sajid A, Rahman H, Ambudkar SV. Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters. Nat Rev Cancer 2023; 23(11):762-79.

[8] Zhang S, Liu Q, Chang M, Pan Y, Yahaya BH, Liu Y, et al. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis 2023; 14(5):340.

[9] Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56(6):1371-83.

[10] Diener C, Keller A, Meese E. Emerging concepts of miRNA therapeutics: from cells to clinic. Trends Genet 2022; 38(6):613-26.

[11] Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev 2022; 182:114113.

[12] Jiménez-Morales JM, Hernández-Cuenca YE, Reyes-Abrahantes A, Ruiz-García H, Barajas-Olmos F, García-Ortiz H, et al. MicroRNA delivery systems in glioma therapy and perspectives: a systematic review. J Control Release 2022; 349:712-30.

[13] Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: a promising therapeutic target in cancer. Int J Mol Sci 2022; 23(19):11502.

[14] Lin Z, He H, Wang M, Liang J. MicroRNA-130a controls bone marrow mesenchymal stem cell differentiation towards the osteoblastic and adipogenic fate. Cell Prolif 2019; 52(6):e12688.

[15] Zhou Y, Chen X, Zhu Z, Bi D, Ma S. MiR-133a delivery to osteoblasts ameliorates mechanical unloading-triggered osteopenia progression in vitro and in vivo. Int Immunopharmacol 2021; 97:107613.

[16] Hu Y, Li X, Zhang Q, Gu Z, Luo Y, Guo J, et al. Exosome-guided bone targeted delivery of Antagomir-188 as an anabolic therapy for bone loss. Bioact Mater 2021; 6(9):2905-13.

[17] Ban E, Kwon TH, Kim A. Delivery of therapeutic miRNA using polymer-based formulation. Drug Deliv Transl Res 2019; 9(6):1043-56.

[18] Sun B, Wu W, Narasipura EA, Ma Y, Yu C, Fenton OS, et al. Engineering nanoparticle toolkits for mRNA delivery. Adv Drug Deliv Rev 2023; 200:115042.

[19] Yu F, Geng D, Kuang Z, Huang S, Cheng Y, Chen Y, et al. Sequentially releasing self-healing hydrogel fabricated with TGF $\beta$3-microspheres and bFGF to facilitate rat alveolar bone defect repair. Asian J Pharm Sci 2022; 17(3):425-34.

[20] Miele D, Xia X, Catenacci L, Sorrenti M, Rossi S, Sandri G, et al. Chitosan oleate coated PLGA nanoparticles as siRNA drug delivery system. Pharmaceutics 2021; 13(10):1716.

[21] Osipova O, Sharoyko V, Zashikhina N, Zakharova N, Tennikova T, Urtti A, et al. Amphiphilic polypeptides for VEGF siRNA delivery into retinal epithelial cells. Pharmaceutics 2020; 12(1):39.

[22] Boufridi A, Quinn RJ. Harnessing the properties of natural products. Annu Rev Pharmacol Toxicol 2018; 58:451-70.

[23] Zhang L, Song J, Kong L, Yuan T, Li W, Zhang W, et al. The strategies and techniques of drug discovery from natural products. Pharmacol Ther 2020;216: 107686.

[24] Wang KX, Chen YP, Lu AP, Du GH, Qin XM, Guan DG, et al. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC. J Ethnopharmacol 2021; 274:114043.

[25] Mukherjee S, Ghosh S, Das DK, Chakraborty P, Choudhury S, Gupta P, Chattopadhyay S, et al. Gold-conjugated green tea nanoparticles for enhanced anti-tumor activities and hepatoprotection-synthesis, characterization and in vitro evaluation. J Nutr Biochem 2015; 26(11):1283-97.

[26] Li NN, Meng XS, Bao YR, Wang S, Li TJ. Evidence for the involvement of COX-2/VEGF and PTEN/Pl3K/AKT pathway the mechanism of oroxin B treated liver cancer. Pharmacogn Mag 2018; 14(54):207-13.

[27] Li N, Men W, Zheng Y, Wang H, Meng X. Oroxin B induces apoptosis by down-regulating microRNA-221 resulting in the inactivation of the PTEN/PI3K/AKT pathway in liver cancer. Molecules 2019; 24(23):4384.

[28] Li D, Li N, Zhang YF, Fu H, Feng M, Schneider D, et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology 2020; 158(8) 2250-65.e20.

[29] Dong L, Zhou H, Zhao M, Gao X, Liu Y, Liu D, et al. Phosphorothioate-modified AP613- 1 specifically targets GPC3 when used for hepatocellular carcinoma cell imaging. Mol Ther Nucleic Acids 2018; 7(13):376-86.

[30] Katas H, HO Alpar. Development and characterisation of chitosan nanoparticles for siRNA delivery. J Control Release 2006; 115(2):216-25.

[31] Wang H, Hou Y, Ma X, Cui L, Bao Y, Xie Y, et al. Multi-omics analysis reveals the mechanisms of action and therapeutic regimens of traditional Chinese medicine, Bufei Jianpi granules: implication for COPD drug discovery. Phytomedicine 2022; 98:153963.

[32] Peng JM, Lin SH, Yu MC, Hsieh SY. CLIC 1 recruits PIP5K1A/C to induce cell-matrix adhesions for tumor metastasis. J Clin Invest 2021; 4(1):e133525131.

[33] Wen Q, Wang Y, Pan Q, Tian R, Zhang D, Qin G, et al. MicroRNA-155-5p promotes neuroinflammation and central sensitization via inhibiting SIRT1 in a nitroglycerin-induced chronic migraine mouse model. J Neuroinflammation 2021; 18(1):287.

[34] Aljobaily N, Viereckl MJ, Hydock DS, Aljobaily H, Wu TY, Busekrus R, et al. Creatine alleviates doxorubicin-induced liver damage by inhibiting liver fibrosis, inflammation, oxidative stress, and cellular senescence. Nutrients 2021; 13(1):41.

[35] Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, et al. Correlative studies of the breast cancer index ( HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki 67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Breast Cancer Res 2022; 24(1):90.

[36] Alvarez M, Benhammou JN, Darci-Maher N, French SW, Han SB, Sinsheimer JS, et al. Human liver single nucleus and single cell RNA sequencing identify a hepatocellular carcinoma-associated cell-type affecting survival. Genome Med 2022; 14(1):50.

[37] Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res 2021; 149:63-101.

[38] Bakr AG, El-Bahrawy AH, Taha HH, Ali FEM. Diosmin enhances the anti-angiogenic activity of sildenafil and pentoxifylline against hepatopulmonary syndrome via regulation of TNF- a /VEGF, IGF-1/PI3K/AKT, and FGF-1/ANG-2 signaling pathways. Eur J Pharmacol 2020; 873:173008.

[39] Ruan GX, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J 2012; 31(7):1692-703.